Why the study?
Does aflibercept suppress angiopoietin-2 in patients with nAMD or DME?
Does aflibercept suppress angiopoietin-2 in patients with nAMD or DME?
This letter questions the conclusions of a prior study regarding aflibercept's ability to suppress Ang-2.
With nAMD or DMEWe read with interest the article titled "Aflibercept Suppression of Angiopoietin-2 in a Rabbit Retinal Vascular Hyperpermeability Model" by Lange and colleagues 1 who reported that antivascular endothelial growth factor-A (VEGF) agents, including aflibercept, suppressed angiopoietin-2 (Ang-2) protein, and retinal/choroidal Ang-2 gene expression in rabbits.After reviewing the article, we have several questions about the model and the conclusions drawn:
No takes yet. Share an insight, caveat, or question.
Avery et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: